Bp 98a blood pressure monitor

Animals were obtained from Vital River Laboratory Animal Technology (Beijing, China), who also performed the blood pressure measurements in spontaneously hypertensive rats (SHRs) with a tail systolic blood pressure (SBP) of over 180 mmHg. Animals were fed a normal diet, and tap water was freely available. SHRs (11 weeks, 240 ± 20 g body weight) were raised at room temperature (25 °C) under a 12 h light/dark cycle. The antihypertensive effect of PPLLFAAL was evaluated by measuring changes in the SBP and DBP after intravenous injection with a single dose of 5 mg/kg body weight. Captopril (5 mg/kg) was used as a positive control, and the negative control group was injected with an equal volume of saline. The SBP and DBP of the rats were measured using the tail-cuff method before administration and at 2, 4, 6, 12, and 24 h post-administration, using a BP-98A blood pressure monitor (Softron Biotechnology, Beijing, China) after heating the SHRs at 37 °C for 30 min in a warming chamber. All the rats received humane care conforming to the National Institutes of Health Guide for Care and Use of Laboratory Animals. This study was approved by the Ethics Committee of Guangdong medical laboratory animal center (No. 20211001).

Male SHRs (10 weeks, 220 ± 20 g body weight) were purchased from Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China). Following an acclimation period of one week, SHRs with systolic blood pressure (SBP) higher than 180 mmHg were randomly divided into groups of ten rats. Animals were housed at 25 °C under a light–dark cycle of 12 h/12 h. TLRFALHGME was injected via tail vein at a dose of 4 mg/kg body weight.
Under the same conditions, a saline group was used as the negative control and captopril (5 mg·kg⁻¹) as the positive control. The SBP of all rats was measured using a BP-98A blood pressure monitor (Softron Biotechnology, Beijing, China) before and after intravenous administration. The rats were all treated humanely according to the guidelines of the National Institutes of Health and Use of Laboratory Animals and approved by the Ethics Committee of Guangdong Medical Laboratory Animal Center (no. 20211001, approved on 9 September 2021).

SHRs (male, 10 weeks, 220 ± 20 g body weight) were supplied by Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China). SHRs with tail SBP over 180 mmHg were randomly divided into groups of 10 rats and housed at 25 °C under a 12 h light/dark cycle. Three doses of GLP (1200, 1500, 1800 mg/kg of body weight, BW) was orally administered to SHRs. The blank group (saline) and Captopril (30 mg/kg·bw) group were used as negative and positive control, respectively. BP-98A blood pressure monitor (Softron Biotechnology, Beijing, China) was used to determine blood pressure by the tail-cuff method. The SBP of the rats was measured at five points: 2 h, 4 h, 6 h, 8 h, and 24 h post-administration. Animals were treated in accordance with the guidelines of the National Institutes of Health and Use of Laboratory Animals.